Recombinetics
Recombinetics is a US-based gene editing company applying TALENs and CRISPR technologies to develop gene-edited swine models for biomedical preclinical research and precision-bred livestock for agricultural markets, serving pharma, biotech, academic medical centers, and global animal producers through subsidiaries Acceligen, Surrogen, and Regenevida.
- Company typePrivate
- Founded2008
- HeadquartersEagan, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Recombinetics does
Recombinetics is a US-based gene editing platform company founded in 2008 and headquartered in New Brighton, Minnesota, operating under the URUS Group holding structure. The company develops and applies proprietary TALENs and CRISPR/Cas9 technologies across two distinct verticals: biomedical preclinical research and agricultural precision breeding. Core technical capabilities include base-pair resolution gene editing, multiplex editing in primary cells, porcine induced pluripotent stem cells (iPSCs), bovine embryonic stem cells, and AI-enhanced bioinformatics for gene editor design.
The biomedical segment (Surrogen, Regenevida sub-brands) provides gene-edited swine models and preclinical services to pharmaceutical, biotech, and academic medical center customers for translational research, gene therapy development, oncology, and xenotransplantation. Notable commercial products include the Swine Reporter Models (SRM-1 and SRM-2) launched in 2024 for in vivo gene therapy and gene editing tracking. The agricultural segment operates through wholly-owned subsidiary Acceligen, which commercializes precision-bred founder animals for cattle, swine, and aquaculture markets globally, including SLICK heat-tolerant cattle, PRRSV-resistant pigs, and naturally castrated swine.
The business model combines professional services revenue (preclinical and custom gene editing engagements), product sales (swine models), licensing/royalties (Acceligen germplasm), and significant non-dilutive grant funding from NIH, NCI, the Bill & Melinda Gates Foundation, and FFAR. Customers include Mayo Clinic, American Preclinical Services, Hendrix Genetics, Kheiron-Biotech, Makana Therapeutics, and ReGen Theranostics. Go-to-market relies on direct enterprise sales, strategic partnerships, and a global conference presence (AACR, ASGCT, BIO).
Recombinetics firmographics
Firmographics- Name
- Recombinetics
- Legal name
- Recombinetics, Inc.
- Website
- https://recombinetics.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Recombinetics is a US-based gene editing company applying TALENs and CRISPR technologies to develop gene-edited swine models for biomedical preclinical research and precision-bred livestock for agricultural markets, serving pharma, biotech, academic medical centers, and global animal producers through subsidiaries Acceligen, Surrogen, and Regenevida.
- Ownership category
- akta.pro rank
Where Recombinetics is headquartered
LocationHeadquarters
- HQ city
- Eagan
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Recombinetics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Preclinical Services: Complete pre-clinical solutions to gene therapy development, from cell editing to animal studies, including gene edited swine husbandry, veterinary oversight, and embryo transfer services. Recurring project-based engagements with biomedical and pharmaceutical customers.
- Custom Gene Editing Services: Custom gene-edited products of the highest quality utilizing cutting-edge genome technologies paired with stringent QA/QC measures. Includes off-the-shelf and custom disease or reporter swine models for academic and commercial partners.
- Swine Model Sales: Sale of gene-edited swine models including Swine Reporter Models (SRM-1, SRM-2) and disease models in large and minipig breeds to business partners, academic institutions, and internal research projects.
- Grant Funding: Non-dilutive grant funding from government and foundations including NIH/NCI (e.g., $4M for glioblastoma swine model development), Bill & Melinda Gates Foundation (for African dairy), FFAR (for castration-free swine), and an SBIR grant from NIH for Osteogenesis Imperfecta research.
- Precision Breeding & Livestock Traits (Acceligen): Commercialization of precision-bred founder animals that generate highly valued germplasm products for the global market, including climate-adapted and disease-resistant traits for cattle, swine, and aquaculture.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | — | Custom preclinical and gene editing services priced on a per-project quote basis |
Go-to-market motion4 records
Distribution channels5 records
Marketing channels7 records
Recombinetics product offering
Product offeringCore offering
Recombinetics develops and provides gene-edited animal models — primarily swine — and related gene editing services for biomedical research, preclinical drug development, xenotransplantation, and precision breeding of food animals. Leveraging proprietary TALENs and CRISPR/Cas9 platforms, the company sells swine models (including Swine Reporter Models and disease models), porcine iPSCs, and offers end-to-end preclinical and gene editing services to pharmaceutical, biotech, academic, and agricultural customers worldwide.
Product overview
Recombinetics operates a platform-plus-modules architecture centered on proprietary gene editing technologies (TALEN and CRISPR) applied across both biomedical and agricultural domains. The core product is gene-edited Swine Models, augmented by sub-products such as Swine Reporter Models (SRM-1, SRM-2) and Porcine Stem Cells (iPSCs), complemented by service modules including Preclinical Services, Gene Editing Services, and Support Services. The portfolio is organized under two sub-brands: Acceligen for agricultural/livestock applications (e.g., polled cattle, wool traits) and Therillume for preclinical brain cancer modeling, with cross-cutting capabilities in xenotransplantation donor pig development.
Differentiator
Problem solved
Functional benefit
Brands
- Acceligen: Wholly-owned subsidiary focused on precision breeding of food animals (cattle, swine, aquaculture) using gene editing, with operations including offices in Brazil.
- Surrogen
- Regenevida
- Therillume
Products and services
- Swine Models Gene-edited pig models designed for biomedical and translational research, including immunodeficient lines (e.g., EBT-3), humanized disease models, and xenotransplantation donor lines. Used by pharma, biotech, and academic researchers for preclinical studies.
- Swine Reporter Models (SRM-1, SRM-2) Reporter pig lines expressing bioluminescent and fluorescent markers (luciferase, fluorescent proteins) that enable in vivo tracking of cells, tumors, and disease progression for preclinical gene therapy and gene editing research.
- Porcine Stem Cells (iPSCs) Induced pluripotent stem cells (iPSCs) derived from porcine species using CRISPR-based reprogramming, supporting regenerative medicine, tissue engineering, disease modeling, and reproductive biotechnology research.
- Preclinical Services Contract research services providing in vivo pharmacology, toxicology, efficacy, and mechanistic studies using gene-edited swine models for biotech and pharmaceutical clients. Includes husbandry, veterinary oversight, and embryo transfer.
- Gene Editing Services Custom gene editing services using proprietary TALEN and CRISPR technologies to introduce, modify, or knock out specific genetic loci in livestock and biomedical animal models, with QA/QC and project delivery for academic and commercial partners.
- Therillume Brain Cancer Models Preclinical oncology offering providing orthotopic and bioluminescent swine brain cancer (glioma) models for translational brain tumor research and therapeutic evaluation. First preclinical test performed in Therillume brain tumor models in 2023.
- Acceligen Precision Breeding Commercialization of precision-bred founder animals that generate highly valued germplasm products for the global market, including climate-adapted, disease-resistant, and welfare-improved traits for cattle, swine, sheep, and aquaculture (e.g., SLICK heat tolerance, polled cattle, KISS1 castration-free swine).
- Support Services Ongoing scientific, technical, and husbandry support services provided alongside model licensing and preclinical engagements for gene-edited animal research customers.
Quantifiable outcome
- First commercial launch of swine reporter models for gene therapy development in 2024
- +9 more outcomes
Companies that use Recombinetics
Customer profileNamed customers9 records
Segments5 records
Ideal customer profiles4 records
Recombinetics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature9 records
Recombinetics partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered flagship, core and minor.
- URUS Group (parent company)flagshipURUS is the parent group; Recombinetics' privacy team is operated out of URUS ([email protected]). The privacy policy states data may be disclosed to URUS affiliates/subsidiaries.
- Makana TherapeuticscoreMakana Therapeutics received a $650,000 KidneyX Artificial Kidney Prize for work to increase the supply of kidney donor organs through pig-to-human xenotransplants, leveraging Recombinetics-derived gene-edited pigs.
- Mayo Clinic (Osteogenesis Imperfecta)coreCollaborative research project with Mayo Clinic to develop the first-ever swine models of Osteogenesis Imperfecta (brittle bone disease). Project led by Adrienne Watson, Ph.D. (Recombinetics VP of R&D) and Mayo Clinic's David Deyle, MD, partially funded by an SBIR grant from the National Institutes of Health.
- Kheiron-Biotech (Proinvesa Group)coreJoint projects in Argentina to produce multiple animal product lines combining Acceligen's gene-editing platform with Kheiron's in vitro embryo production, cloning, and gene-editing platform and infrastructure. Aimed at commercializing precision-bred founder animals with adaptability traits for climate change.
- TARGET-TB (Bovine Tuberculosis Research Consortium)minorResearch collaboration to develop genome editing solutions for bovine tuberculosis (BTB).
- Hendrix Genetics (Hypor)flagshipAlliance to End Surgical Castration of Swine — combining Hendrix Genetics' commercially relevant swine genetics with Acceligen's proprietary precision breeding methods to develop naturally castrated male piglets. Alliance made possible by a grant from the Foundation for Food and Agriculture Research (FFAR).
- American Preclinical Services (APS)corePartnership with American Preclinical Services to improve glioblastoma outcomes using Recombinetics' engineered swine models.
- Mayo Clinic (Regenerative Medicine)flagshipMulti-project collaborative R&D agreement with Mayo Clinic to bioengineer human stem cells within swine models for exo-transplantation back into humans. Combines Recombinetics' Regenevida biomedical swine with ReGen Theranostics' stem cells. Project leads: Dr. Timothy Nelson, M.D., Ph.D. (Mayo Clinic) and Dan Carlson, Ph.D. (Recombinetics SVP R&D).
- ReGen TheranosticscoreProvides quality control processes and high-quality stem cells used in the Mayo Clinic collaboration on exo-transplantation within Recombinetics' Regenevida swine models.
- UC DavisminorResearch collaboration on the polled (hornless) cattle project; UC Davis conducted validation breeding of the first polled progeny and confirmed the FDA-discovered plasmid integration.
Scale indicators11 records
Recent moves7 records
Expansion highlights7 records
Recombinetics competitors and assessment
Company assessmentDirect peers
- eGenesis: Gene-edited pig platform for xenotransplantation with PERV-knockout donor pigs. Most directly comparable to Recombinetics' biomedical/xenotransplantation thesis, including use of CRISPR in porcine models and pursuit of pig-to-human organ applications.
- Revivicor (United Therapeutics): Pioneered GalSafe pigs (FDA-approved) and 10-gene-edited pig hearts used in early human transplants. Closest historical precedent for Recombinetics' biomedical swine model and xenotransplantation work, with deeper clinical pipeline.
- Calyxt: Gene-editing platform applied to agricultural crops and livestock. Comparable to Acceligen's agricultural commercialization mission via TALEN/CRISPR-derived non-transgenic products, with a similar public-market journey (now private under Cibus merger).
- Pairwise: CRISPR-based agricultural company developing gene-edited fruits, row crops, and livestock with consumer and producer focus. Comparable to Acceligen's agricultural precision-breeding thesis and similar stage in commercializing non-GMO gene-edited products.
Broad incumbents
- Intrexon / Precigen: Diversified synthetic biology platform with gene-edited animal assets (e.g., EnviroFlight, AquaBounty salmon). Comparable as a broader incumbent in gene-edited animal commercialization spanning agricultural and biomedical markets.
- Genus plc: Global animal genetics leader in porcine and bovine breeding with PRRSV-resistant pig program (via PIC). Comparable to Acceligen as a customer/competitor in the precision-bred livestock space and as a potential strategic partner or acquirer.
- CRISPR Therapeutics: Leading clinical-stage CRISPR gene editing company with Casgevy approval. While focused on human therapeutics, its platform IP and large capital base position it as an adjacent/incumbent competitor for large-animal gene editing applications.
Emerging players
- Caribou Biosciences: Clinical-stage CRISPR genome editing company with allogeneic cell therapy pipeline. Comparable emerging player in next-generation gene editing applications, smaller than the major incumbents but technically credible.
Regional players
- Topigs Norsvin: Global pig genetics supplier with deep European footprint. Comparable to Acceligen's swine trait work and as a competing channel for gene-edited swine genetics, particularly relevant given Hendrix Genetics partnership.
Others
- MAKI Animal Clinic (Tonisity / Makana-aligned services): Veterinary and preclinical CRO services supporting large-animal research. Considered adjacent ecosystem participant for Recombinetics' biomedical preclinical services and gene-edited animal husbandry value chain.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Recombinetics social profiles
Digital presenceRecombinetics compliance and trust
Trust signalCompliance1 record
Recombinetics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Recombinetics leadership team
Management profileNumber of profiles
Profiles9 records
Recombinetics subsidiaries and ownership
Company hierarchySubsidiaries4 records
Recombinetics funding detail
Funding detailFunding overview
Funding rounds12 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Recombinetics M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Recombinetics
What does Recombinetics do?
Recombinetics develops and provides gene-edited animal models — primarily swine — and related gene editing services for biomedical research, preclinical drug development, xenotransplantation, and precision breeding of food animals. Leveraging proprietary TALENs and CRISPR/Cas9 platforms, the company sells swine models (including Swine Reporter Models and disease models), porcine iPSCs, and offers end-to-end preclinical and gene editing services to pharmaceutical, biotech, academic, and agricultural customers worldwide.
Is Recombinetics a public or private company?
Recombinetics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Recombinetics founded?
Recombinetics was founded in 2008. It employs 11 to 50 people.
Where is Recombinetics based?
Recombinetics is headquartered in Eagan, United States, in the North America region.
How does Recombinetics make money?
Five revenue lines are on record. Preclinical Services are the primary driver. The others are custom Gene Editing Services, swine Model Sales, grant Funding and precision Breeding & Livestock Traits (Acceligen).
Who are Recombinetics's main competitors?
Direct peers on record are eGenesis, Revivicor (United Therapeutics), Calyxt and Pairwise. Broad incumbents are Intrexon / Precigen, Genus plc and CRISPR Therapeutics. Caribou Biosciences is listed as an emerging player. Topigs Norsvin is listed as a regional player. MAKI Animal Clinic (Tonisity / Makana-aligned services) is listed as an others.
Does Recombinetics have an API?
No public API is recorded for Recombinetics.